DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
...
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 30
- Registration Number
- NCT01220726
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 192
- Registration Number
- NCT01180348
- Locations
- 🇧🇷
LAL Clinica Pesquisa e Desenvolvimento Ltda, Valinhos, Sao Paulo, Brazil
Treatment of Notalgia Paresthetica With Xeomin
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Innovaderm Research Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01098019
- Locations
- 🇨🇦
Innovaderm Research Inc, Montreal, Quebec, Canada
Botox Cosmetic and the Young Patient With Glabellar Furrows
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 50
- Registration Number
- NCT00856999
Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 25
- Registration Number
- NCT00660192
- Locations
- 🇺🇸
Yale Physician's Building, 800 Howard Ave, lower level,, New Haven, Connecticut, United States
The Effect of Botox Injection on Postural Stability of Cerebral Palsy (CP) Children
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00651339
- Locations
- 🇮🇱
Soroka University Medical Center, Beer-Sheva, Israel
Botox Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Sheffield Children's NHS Foundation Trust
- Registration Number
- NCT00624299
- Locations
- 🇬🇧
Clinical Research Facility, Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom
Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 7
- Registration Number
- NCT00529386
- Locations
- 🇨🇦
Centre for Advanced Urological Research, Kingston, Ontario, Canada
This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
- Conditions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2007-05-30
- Lead Sponsor
- Urological Sciences Research Foundation
- Target Recruit Count
- 40
- Registration Number
- NCT00479596
- Locations
- 🇺🇸
Urological Sciences Research Foundation, Culver City, California, United States
A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 31
- Registration Number
- NCT00345332
- Locations
- 🇺🇸
University of California at Davis, Sacramento, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.